image
Healthcare - Biotechnology - NASDAQ - US
$ 2.9
0.694 %
$ 312 M
Market Cap
-1.1
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one RCKT stock under the worst case scenario is HIDDEN Compared to the current market price of 2.9 USD, Rocket Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one RCKT stock under the base case scenario is HIDDEN Compared to the current market price of 2.9 USD, Rocket Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one RCKT stock under the best case scenario is HIDDEN Compared to the current market price of 2.9 USD, Rocket Pharmaceuticals, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart RCKT

image
$12.0$12.0$11.0$11.0$10.0$10.0$9.0$9.0$8.0$8.0$7.0$7.0$6.0$6.0$5.0$5.0$4.0$4.0$3.0$3.0$2.0$2.015 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '25
FINANCIALS
0 REVENUE
0.00%
-273 M OPERATING INCOME
-5.22%
-259 M NET INCOME
-5.35%
-210 M OPERATING CASH FLOW
-7.60%
132 M INVESTING CASH FLOW
234.30%
186 M FINANCING CASH FLOW
-10.87%
0 REVENUE
0.00%
-64.4 M OPERATING INCOME
-2.70%
-61.3 M NET INCOME
-1.67%
-55.8 M OPERATING CASH FLOW
-18.85%
-58 M INVESTING CASH FLOW
-53.24%
0 FINANCING CASH FLOW
0.00%
Balance Sheet Rocket Pharmaceuticals, Inc.
image
Current Assets 378 M
Cash & Short-Term Investments 372 M
Receivables 0
Other Current Assets 5.85 M
Non-Current Assets 150 M
Long-Term Investments 0
PP&E 83.3 M
Other Non-Current Assets 66.2 M
70.56 %15.79 %12.54 %Total Assets$527.7m
Current Liabilities 40.7 M
Accounts Payable 0
Short-Term Debt 2.86 M
Other Current Liabilities 37.8 M
Non-Current Liabilities 23.8 M
Long-Term Debt 0
Other Non-Current Liabilities 23.8 M
4.43 %58.68 %36.89 %Total Liabilities$64.5m
EFFICIENCY
Earnings Waterfall Rocket Pharmaceuticals, Inc.
image
Revenue 0
Cost Of Revenue 0
Gross Profit 0
Operating Expenses 273 M
Operating Income -273 M
Other Expenses -14.5 M
Net Income -259 M
00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)(300m)(300m)000(273m)(273m)14m(259m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-55.86% ROE
-55.86%
-49.03% ROA
-49.03%
-55.77% ROIC
-55.77%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Rocket Pharmaceuticals, Inc.
image
00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -259 M
Depreciation & Amortization 9.38 M
Capital Expenditures -5.86 M
Stock-Based Compensation 43.9 M
Change in Working Capital 1.92 M
Others -4.27 M
Free Cash Flow -216 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Rocket Pharmaceuticals, Inc.
image
Wall Street analysts predict an average 1-year price target for RCKT of $26.4 , with forecasts ranging from a low of $2 to a high of $45 .
RCKT Lowest Price Target Wall Street Target
2 USD -31.03%
RCKT Average Price Target Wall Street Target
26.4 USD 810.92%
RCKT Highest Price Target Wall Street Target
45 USD 1451.72%
Price
Max Price Target
Min Price Target
Average Price Target
454540403535303025252020151510105500Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 20
6. Ownership
Insider Ownership Rocket Pharmaceuticals, Inc.
image
Sold
0-3 MONTHS
89.5 K USD 5
3-6 MONTHS
418 K USD 6
6-9 MONTHS
343 K USD 6
9-12 MONTHS
422 K USD 6
Bought
0 USD 0
0-3 MONTHS
102 K USD 2
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Rocket Pharmaceuticals To Contact Him Directly To Discuss Their Options globenewswire.com - 6 days ago
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RCKT NEW YORK, July 04, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) between February 27, 2025 and May 26, 2025, both dates inclusive (the “Class Period”), of the important August 11, 2025 lead plaintiff deadline. globenewswire.com - 1 week ago
Contact Levi & Korsinsky by August 11, 2025 Deadline to Join Class Action Against Rocket Pharmaceuticals, Inc. (RCKT) NEW YORK, July 03, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT) of a class action securities lawsuit. globenewswire.com - 1 week ago
RCKT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit NEW YORK, July 03, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. (“Rocket” or “the Company”) (NASDAQ: RCKT) and certain of its officers. globenewswire.com - 1 week ago
RCKT INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit SAN DIEGO , July 3, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) securities between February 27, 2025 and May 26, 2025, both dates inclusive (the "Class Period"), have until Monday, August 11, 2025 to seek appointment as lead plaintiff of the Rocket Pharmaceuticals class action lawsuit.  Captioned Ho v. prnewswire.com - 1 week ago
Rocket Pharmaceuticals, Inc. (RCKT) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit LOS ANGELES , July 3, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT) have opportunity to lead the securities fraud class action lawsuit. prnewswire.com - 1 week ago
Investors in Rocket Pharmaceuticals, Inc. Should Contact The Gross Law Firm Before August 11, 2025 to Discuss Your Rights - RCKT NEW YORK , July 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT). Shareholders who purchased shares of RCKT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. prnewswire.com - 1 week ago
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson  Encourages Investors Who Suffered Losses In Rocket Pharmaceuticals To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Rocket Pharmaceuticals  between February 27, 2025 and May 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext. 1310). [You may also click here for additional information] NEW YORK , July 3, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT) and reminds investors of the August 11, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. prnewswire.com - 1 week ago
Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class Action Amid Protocol Change and FDA's Clinical Hold on Gene Therapy Trial – Hagens Berman SAN FRANCISCO, July 02, 2025 (GLOBE NEWSWIRE) -- A securities class action lawsuit styled Ho v. Rocket Pharmaceuticals, Inc., et al., No. 3:25-cv-10049 (D. N.J.) has been filed and seeks to represent investors who purchased or otherwise acquired Rocket Pharmaceuticals securities between February 27, 2025 and May 26, 2025. globenewswire.com - 1 week ago
RCKT LAWSUIT ALERT: The Gross Law Firm Notifies Rocket Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT). globenewswire.com - 1 week ago
RCKT Investors Have Opportunity to Lead Rocket Pharmaceuticals, Inc. Securities Fraud Lawsuit NEW YORK , July 2, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) between February 27, 2025 and May 26, 2025, both dates inclusive (the "Class Period"), of the important August 11, 2025 lead plaintiff deadline. So what: If you purchased Rocket Pharmaceuticals securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. prnewswire.com - 1 week ago
Rocket Pharmaceuticals, Inc. (RCKT) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit BENSALEM, Pa. , July 2, 2025 /PRNewswire/ -- The Law Offices of Howard G. prnewswire.com - 1 week ago
8. Profile Summary

Rocket Pharmaceuticals, Inc. RCKT

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 312 M
Dividend Yield 0.00%
Description Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey.
Contact 9 Cedarbrook Drive, Cranbury, NJ, 08512 https://rocketpharma.com
IPO Date Feb. 18, 2015
Employees 299
Officers Dr. Kinnari Patel M.B.A., Pharm.D. Head of R&D, President & Chief Operating Officer Kevin Giordano Director of Corporate Communications Ms. Sarbani Chaudhuri M.B.A. Chief Commercial & Medical Affairs Officer Mr. Aaron Ondrey Chief Financial Officer Dr. Gaurav D. Shah M.D. Chief Executive Officer & Director Dr. Jonathan Schwartz M.D. Chief Medical & Gene Therapy Officer Dr. Gayatri R. Rao J.D., M.D. Senior Vice President of Clinical Safety & Chief Regulatory Officer Ms. Isabel Carmona J.D. Chief People Officer Mr. Martin Louis Wilson J.D. General Counsel, Chief Compliance Officer & Chief Corporate Officer Mr. Raj Prabhakar M.B.A. Chief Business Officer